New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2012
16:06 EDTARNAArena Pharmaceuticals reports Q4 EPS (16c), consensus (15c)
Reports Q4 revenue $2.08M, consensus $3.49M.
News For ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 29, 2015
08:22 EDTARNAArena Pharmaceuticals' pain treatment candidate shows positive Phase 1 results
Arena Pharmaceuticals announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 receptor currently in development for the treatment of pain and potentially fibrotic diseases. The Phase 1 clinical trial showed that APD371 was well tolerated at drug levels greatly exceeding those anticipated as needed for activating the CB2 receptor.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use